Table 2.
Case | Sex | Age (y) | Diagnosis | Prior therapy | Cohort/dose schedule | Total |
---|---|---|---|---|---|---|
1 | M | 72 | T-cell large granular lymphocyte leukemia | Three cycles: Cyclophosphamide Vindesine Prednisone IFN; Three cycles: Fludarabine Cyclophosphamide IFN |
Cohort 8: day 0, 0.8 mg/kg Weekly | 6.4 mg/kg over 8 wk |
2 | F | 65 | T-cell large granular lymphocyte leukemia | Cyclosporine Methotrexate |
Cohort 9 Day 0, 3.4 mg/kg Weekly | 64.6 mg/kg over 19 wk |
3 | F | 58 | ATLL Acute subtype |
Eight cycles: Cyclophosphamide Doxorubicin Vincristine Prednisone |
Cohort 9 Day 0, 3.4 mg/kg Weekly | 34 mg/kg over 10 wk |
4 | F | 56 | Cutaneous T-cell lymphoma Stage IV | Topical steroids Psoaralen and UV light therapy Local radiation |
Cohort 6 Day 0, 0.4 mg/kg Day 1, 1.2 mg/kg Day 3, 1.8 mg/kg Every other week |
6.8 mg/kg over 2 wk |
3 mo cyclosporine | 189 | Extranodal non-Hodgkin’s lymphoma of gastrointestinal tract Monoclonal process Peak EBV viral load 1,600 |
Complete remission post-chemotherapy | |||
None | 147 | Mediastinal adenopathy Unable to determine clonality Peak EBV viral load 910 |
Complete remission after stopping siplizumab | |||
One cycle: denileukin diftitox | 55 | Extranodal non-Hodgkin’s lymphoma Monoclonal process EBV viral load unavailable |
Death from ATLL progression | |||
Six cycles: romidepsin Two cycles: gemcitabine |
309 | Extensive adenopathy Polyclonal process Peak EBV viral load 1.4 × 106 |
Complete remission with rituximab |